Zevra Therapeutics (ZVRA) Financials

$11.12 +0.07 (+0.63%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$11.42 +0.30 (+2.70%)

As of 07:39 AM Eastern

Annual Income Statements for Zevra Therapeutics

This table shows Zevra Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-27	-46	-106
Consolidated Net Income / (Loss)	-27	-46	-106
Net Income / (Loss) Continuing Operations	-27	-46	-106
Total Pre-Tax Income	-27	-46	-90
Total Operating Income	-43	-50	-87
Total Gross Profit	9.94	25	16
Total Revenue	10	27	24
Operating Revenue	10	27	24
Total Cost of Revenue	0.22	2.17	7.42
Operating Cost of Revenue	0.22	2.17	7.42
Total Operating Expenses	53	75	103
Selling, General & Admin Expense	15	34	55
Research & Development Expense	37	40	42
Amortization Expense	-	0.77	6.24
Total Other Income / (Expense), net	16	3.56	-3.14
Interest Expense	-1.18	-3.04	5.18
Other Income / (Expense), net	15	0.52	2.04
Income Tax Expense	-0.03	0.00	15
Basic Earnings per Share	($0.78)	($1.30)	($2.28)
Weighted Average Basic Shares Outstanding	34.49M	35.45M	46.25M
Weighted Average Diluted Shares Outstanding	34.54M	43.43M	54.12M
Weighted Average Basic & Diluted Shares Outstanding	34.54M	43.43M	54.12M

This table shows Zevra Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-6.62	5.75	-13	-2.57	-10	-20	-17	-20	-33	-36
Consolidated Net Income / (Loss)	-6.62	5.75	-13	-2.57	-10	-20	-17	-20	-33	-36
Net Income / (Loss) Continuing Operations	-6.62	5.75	-13	-2.57	-10	-20	-17	-20	-33	-36
Total Pre-Tax Income	-6.65	6.47	-13	-2.65	-10	-20	-17	-20	-33	-20
Total Operating Income	-6.63	-9.31	-13	-6.25	-15	-15	-20	-24	-27	-15
Total Gross Profit	2.73	2.00	3.05	7.79	2.75	12	3.25	0.88	1.39	11
Total Revenue	2.87	2.02	3.18	8.47	2.90	13	3.43	4.45	3.70	12
Operating Revenue	2.87	2.02	3.18	8.47	2.90	13	3.43	4.45	3.70	12
Total Cost of Revenue	0.14	0.02	0.13	0.68	0.14	1.23	0.18	3.57	2.30	1.37
Operating Cost of Revenue	0.14	0.02	0.13	0.68	0.14	1.23	0.18	3.57	2.30	1.37
Total Operating Expenses	9.36	11	16	14	18	27	24	25	29	26
Selling, General & Admin Expense	3.97	4.77	7.23	6.61	5.82	15	9.93	13	16	16
Research & Development Expense	5.39	6.54	8.66	7.43	12	11	12	11	11	8.35
Amortization Expense	-	-	0.00	0.00	0.00	0.77	1.53	1.55	1.55	1.62
Total Other Income / (Expense), net	-0.02	16	-0.49	3.61	5.17	-4.74	3.79	3.94	-5.92	-4.95
Interest Expense	-0.09	-0.65	-0.86	-1.36	-1.37	0.55	-0.19	1.84	1.26	2.27
Other Income / (Expense), net	-0.12	15	-1.35	2.25	3.80	-4.19	3.60	5.78	-4.66	-2.69
Income Tax Expense	-0.03	0.72	-0.10	-0.07	0.18	-	-0.07	0.07	0.00	15
Basic Earnings per Share	($0.19)	$0.16	($0.38)	($0.08)	($0.30)	($0.54)	($0.40)	($0.48)	($0.69)	($0.71)
Weighted Average Basic Shares Outstanding	34.49M	34.49M	34.47M	33.90M	34.72M	35.45M	41.78M	41.90M	47.81M	46.25M
Weighted Average Diluted Shares Outstanding	34.50M	34.54M	33.88M	33.93M	36.22M	43.43M	41.85M	52.62M	53.38M	54.12M
Weighted Average Basic & Diluted Shares Outstanding	34.50M	34.54M	33.88M	33.93M	36.22M	43.43M	41.85M	52.62M	53.38M	54.12M

This table details how cash moves in and out of Zevra Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-47	-22	-9.26
Net Cash From Operating Activities	-19	-34	-70
Net Cash From Continuing Operating Activities	-19	-34	-70
Net Income / (Loss) Continuing Operations	-27	-46	-106
Consolidated Net Income / (Loss)	-27	-46	-106
Depreciation Expense	0.94	1.01	6.39
Amortization Expense	-	0.00	-0.89
Non-Cash Adjustments To Reconcile Net Income	7.79	8.74	38
Changes in Operating Assets and Liabilities, net	-0.68	2.77	-7.19
Net Cash From Investing Activities	-37	-17	-22
Net Cash From Continuing Investing Activities	-37	-17	-22
Purchase of Property, Plant & Equipment	-0.09	-0.30	0.00
Acquisitions	-14	-30	-6.00
Purchase of Investments	-24	-46	-41
Sale and/or Maturity of Investments	1.33	59	25
Net Cash From Financing Activities	8.35	28	82
Net Cash From Continuing Financing Activities	8.35	28	82
Repayment of Debt	-0.02	-18	-45
Repurchase of Common Equity	-4.72	-3.45	0.00
Issuance of Debt	13	42	59
Issuance of Common Equity	0.32	6.32	66
Other Financing Activities, net	-0.03	0.69	2.34
Effect of Exchange Rate Changes	0.20	-	0.45
Cash Interest Paid	0.32	0.46	5.26

This table details how cash moves in and out of Zevra Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-6.72	-4.59	-25	26	-23	-0.22	-0.20	-3.59	15	-20
Net Cash From Operating Activities	-6.60	-4.46	-4.05	-8.70	-4.63	-16	-16	-19	-18	-16
Net Cash From Continuing Operating Activities	-6.60	-4.46	-4.05	-8.70	-4.63	-16	-16	-19	-18	-16
Net Income / (Loss) Continuing Operations	-6.62	5.75	-13	-2.57	-10	-20	-17	-20	-33	-36
Consolidated Net Income / (Loss)	-6.62	5.75	-13	-2.57	-10	-20	-17	-20	-33	-36
Depreciation Expense	0.40	0.30	0.08	0.08	0.06	0.79	1.56	1.56	1.62	1.65
Non-Cash Adjustments To Reconcile Net Income	1.90	-15	3.60	1.66	-1.31	4.79	0.06	2.37	11	24
Changes in Operating Assets and Liabilities, net	-2.28	3.99	5.50	-7.87	6.99	-1.85	-1.16	-3.12	2.46	-5.37
Net Cash From Investing Activities	0.27	-0.06	-18	34	-44	11	15	-0.13	-31	-5.47
Net Cash From Continuing Investing Activities	0.27	-0.06	-18	34	-44	11	15	-0.13	-31	-5.47
Purchase of Investments	-	-0.03	-	-	-54	25	-	-	-41	0.33
Sale and/or Maturity of Investments	0.30	-	-18	52	9.50	16	15	-	10	0.20
Net Cash From Financing Activities	-0.41	-0.26	-3.75	0.95	26	5.00	1.22	15	65	0.80
Net Cash From Continuing Financing Activities	-0.41	-0.26	-3.75	0.95	26	5.00	1.22	15	65	0.80
Issuance of Common Equity	-	-	0.00	0.17	0.05	6.11	1.22	0.48	65	-0.89
Other Financing Activities, net	-0.42	-0.63	-0.42	1.11	-0.00	-	0.00	0.65	-	1.68
Cash Interest Paid	0.12	0.16	0.07	0.19	0.20	-	0.14	2.00	1.53	1.59

This table presents Zevra Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	115	172	178
Total Current Assets	93	87	86
Cash & Equivalents	65	43	34
Short-Term Investments	17	25	36
Accounts Receivable	8.30	17	11
Inventories, net	-	0.00	1.97
Prepaid Expenses	1.69	1.82	4.05
Plant, Property, & Equipment, net	0.79	0.74	0.36
Total Noncurrent Assets	22	85	92
Long-Term Investments	20	0.00	6.01
Goodwill	0.00	4.70	4.70
Intangible Assets	0.00	69	69
Other Noncurrent Operating Assets	1.71	11	12
Total Liabilities & Shareholders' Equity	115	172	178
Total Liabilities	40	110	138
Total Current Liabilities	12	74	34
Short-Term Debt	0.00	38	0.00
Accounts Payable	6.17	28	25
Other Current Liabilities	5.85	7.62	8.61
Total Noncurrent Liabilities	28	37	104
Long-Term Debt	13	5.07	60
Noncurrent Deferred Revenue	-	0.00	14
Other Noncurrent Operating Liabilities	15	32	30
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	75	62	40
Total Preferred & Common Equity	75	62	40
Preferred Stock	0.00	0.00	0.00
Total Common Equity	75	62	40
Common Stock	436	473	555
Retained Earnings	-354	-400	-505
Treasury Stock	-7.54	-11	-11
Accumulated Other Comprehensive Income / (Loss)	0.11	-0.04	0.63

This table presents Zevra Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	120	107	106	139	151	144	192
Total Current Assets	85	104	103	137	63	61	99
Cash & Equivalents	70	40	66	43	43	39	54
Short-Term Investments	5.83	55	21	40	9.87	10.00	35
Accounts Receivable	6.58	7.82	14	9.93	8.31	8.95	7.79
Prepaid Expenses	2.66	1.17	2.02	1.66	1.87	2.69	2.28
Plant, Property, & Equipment, net	0.85	0.74	0.69	0.64	0.70	0.68	0.61
Total Noncurrent Assets	34	1.57	1.40	1.33	88	83	92
Long-Term Investments	31	0.00	0.00	0.00	-	-	6.11
Goodwill	-	-	-	-	4.70	4.70	4.70
Intangible Assets	-	-	-	-	68	66	71
Other Noncurrent Operating Assets	2.10	1.57	1.40	1.33	15	12	10
Total Liabilities & Shareholders' Equity	120	107	106	139	151	144	192
Total Liabilities	26	35	37	72	102	112	122
Total Current Liabilities	8.43	16	18	22	30	30	34
Short-Term Debt	-	-	-	-	0.00	0.00	0.00
Accounts Payable	4.28	10	11	13	23	20	24
Other Current Liabilities	4.15	5.52	7.74	8.63	7.12	10.00	10
Total Noncurrent Liabilities	17	20	19	50	73	81	87
Long-Term Debt	13	13	13	44	43	58	59
Other Noncurrent Operating Liabilities	4.53	6.66	6.06	5.92	30	23	28
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	94	71	68	67	49	32	70
Total Preferred & Common Equity	94	71	68	67	49	32	70
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	94	71	68	67	49	32	70
Common Stock	401	403	405	418	476	479	550
Retained Earnings	-300	-320	-325	-339	-416	-436	-470
Treasury Stock	-7.54	-11	-11	-11	-11	-11	-11
Accumulated Other Comprehensive Income / (Loss)	0.20	-0.06	-0.23	-0.22	0.14	0.42	-0.12

This table displays calculated financial ratios and metrics derived from Zevra Therapeutics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	-64.53%	170.26%	-14.02%
EBITDA Growth	-433.40%	-77.83%	-65.27%
EBIT Growth	-463.27%	-75.42%	-73.08%
NOPAT Growth	-650.72%	-16.54%	-75.40%
Net Income Growth	-212.94%	-72.00%	-129.13%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-279.30%	-79.17%	-107.74%
Free Cash Flow Firm Growth	-512.15%	-457.68%	44.91%
Invested Capital Growth	-2,196.46%	347.16%	-35.86%
Revenue Q/Q Growth	-5.22%	65.80%	-3.58%
EBITDA Q/Q Growth	24.62%	-105.40%	1.50%
EBIT Q/Q Growth	23.49%	-105.15%	1.44%
NOPAT Q/Q Growth	-17.93%	-13.35%	-0.30%
Net Income Q/Q Growth	24.00%	-125.65%	-17.67%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-23.93%	-53.56%	-0.13%
Free Cash Flow Firm Q/Q Growth	36.06%	-45.92%	27.76%
Invested Capital Q/Q Growth	-1,864.08%	32.15%	-28.71%
Profitability Metrics	-	-	-
Gross Margin	97.82%	92.09%	68.59%
EBITDA Margin	-266.11%	-175.10%	-336.55%
Operating Margin	-418.91%	-180.63%	-368.47%
EBIT Margin	-275.40%	-178.76%	-359.83%
Profit (Net Income) Margin	-263.48%	-167.69%	-446.85%
Tax Burden Percent	99.88%	100.00%	117.05%
Interest Burden Percent	95.79%	93.81%	106.09%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-316.15%	-201.14%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-296.46%	16.61%
Return on Net Nonoperating Assets (RNNOA)	0.00%	248.92%	-6.70%
Return on Equity (ROE)	-26.48%	-67.23%	-207.84%
Cash Return on Invested Capital (CROIC)	0.00%	-234.58%	-157.45%
Operating Return on Assets (OROA)	-22.54%	-34.13%	-48.49%
Return on Assets (ROA)	-21.57%	-32.02%	-60.21%
Return on Common Equity (ROCE)	-26.48%	-67.23%	-207.84%
Return on Equity Simple (ROE_SIMPLE)	-35.64%	-74.44%	-266.00%
Net Operating Profit after Tax (NOPAT)	-30	-35	-61
NOPAT Margin	-293.23%	-126.44%	-257.93%
Net Nonoperating Expense Percent (NNEP)	2.78%	-19.69%	-217.75%
Return On Investment Capital (ROIC_SIMPLE)	-	-33.19%	-61.41%
Cost of Revenue to Revenue	2.18%	7.91%	31.41%
SG&A Expenses to Revenue	148.00%	124.96%	232.37%
R&D to Revenue	368.72%	144.95%	178.28%
Operating Expenses to Revenue	516.72%	272.72%	437.06%
Earnings before Interest and Taxes (EBIT)	-28	-49	-85
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-27	-48	-79
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.11	3.83	11.22
Price to Tangible Book Value (P/TBV)	2.11	0.00	0.00
Price to Revenue (P/Rev)	15.59	8.64	18.85
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	5.75	18.14
Enterprise Value to Revenue (EV/Rev)	6.72	7.73	18.18
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.17	0.69	1.50
Long-Term Debt to Equity	0.17	0.08	1.50
Financial Leverage	-1.08	-0.84	-0.40
Leverage Ratio	1.23	2.10	3.45
Compound Leverage Factor	1.18	1.97	3.66
Debt to Total Capital	14.56%	40.87%	60.00%
Short-Term Debt to Total Capital	0.00%	36.03%	0.00%
Long-Term Debt to Total Capital	14.56%	4.84%	60.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	85.44%	59.13%	40.00%
Debt to EBITDA	-0.47	-0.89	-0.75
Net Debt to EBITDA	3.33	0.52	0.20
Long-Term Debt to EBITDA	-0.47	-0.11	-0.75
Debt to NOPAT	-0.43	-1.23	-0.98
Net Debt to NOPAT	3.02	0.72	0.26
Long-Term Debt to NOPAT	-0.43	-0.15	-0.98
Altman Z-Score	-1.80	-2.65	-3.13
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.72	1.18	2.53
Quick Ratio	7.58	1.15	2.35
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-16	-87	-48
Operating Cash Flow to CapEx	-20,125.81%	-11,329.39%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-9.21
Operating Cash Flow to Interest Expense	0.00	0.00	-13.46
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-13.46
Efficiency Ratios	-	-	-
Asset Turnover	0.08	0.19	0.13
Accounts Receivable Turnover	2.07	2.14	1.69
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	12.11	35.90	43.25
Accounts Payable Turnover	0.05	0.13	0.28
Days Sales Outstanding (DSO)	176.50	170.64	215.53
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	7,568.82	2,903.54	1,325.23
Cash Conversion Cycle (CCC)	-7,392.32	-2,732.90	-1,109.70
Capital & Investment Metrics	-	-	-
Invested Capital	-15	37	24
Invested Capital Turnover	-1.30	2.50	0.78
Increase / (Decrease) in Invested Capital	-14	52	-13
Enterprise Value (EV)	68	212	429
Market Capitalization	158	237	445
Book Value per Share	$2.18	$1.71	$0.74
Tangible Book Value per Share	$2.18	($0.33)	($0.64)
Total Capital	88	105	99
Total Debt	13	43	60
Total Long-Term Debt	13	5.07	60
Net Debt	-90	-25	-16
Capital Expenditures (CapEx)	0.09	0.30	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.04	-17	-18
Debt-free Net Working Capital (DFNWC)	81	51	52
Net Working Capital (NWC)	81	13	52
Net Nonoperating Expense (NNE)	-3.02	11	45
Net Nonoperating Obligations (NNO)	-90	-25	-16
Total Depreciation and Amortization (D&A)	0.94	1.01	5.50
Debt-free, Cash-free Net Working Capital to Revenue	-20.04%	-61.25%	-74.26%
Debt-free Net Working Capital to Revenue	795.31%	185.42%	220.07%
Net Working Capital to Revenue	795.31%	48.13%	220.07%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.20)	($1.30)	($2.28)
Adjusted Weighted Average Basic Shares Outstanding	34.49M	35.45M	46.25M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	34.54M	43.43M	54.12M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	34.54M	43.43M	54.12M
Normalized Net Operating Profit after Tax (NOPAT)	-30	-35	-61
Normalized NOPAT Margin	-293.23%	-126.44%	-257.93%
Pre Tax Income Margin	-263.80%	-167.69%	-381.76%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	-16.42
NOPAT to Interest Expense	0.00	0.00	-11.77
EBIT Less CapEx to Interest Expense	0.00	0.00	-16.42
NOPAT Less CapEx to Interest Expense	0.00	0.00	-11.77
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-17.64%	-7.49%	0.00%

This table displays calculated financial ratios and metrics derived from Zevra Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	46.26%	-21.69%	-19.90%	551.54%	0.73%	538.97%	7.84%	-47.47%	27.63%	-6.79%
EBITDA Growth	-247.67%	325.55%	-640.21%	84.24%	-81.25%	-403.37%	-8.67%	-319.18%	-163.87%	11.34%
EBIT Growth	-256.77%	309.55%	-619.80%	84.04%	-71.47%	-432.54%	-19.08%	-350.04%	-176.44%	6.43%
NOPAT Growth	-198.20%	-316.10%	-590.21%	74.76%	-131.87%	-28.17%	-59.66%	-280.60%	-77.73%	-1.71%
Net Income Growth	-276.12%	312.73%	-609.07%	89.30%	-56.70%	-445.95%	-25.76%	-674.39%	-220.49%	-79.67%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-141.69%	-426.18%	-13.85%	-112.09%	29.86%	-262.12%	-299.63%	-119.54%	-291.98%	-0.57%
Free Cash Flow Firm Growth	-27.05%	265.06%	-18.89%	95.79%	-982.07%	-1,140.65%	-1,584.23%	-9,182.88%	38.15%	103.90%
Invested Capital Growth	-424.79%	-2,196.46%	-565.65%	-148.51%	3,773.42%	347.16%	456.55%	774.15%	18.89%	-35.86%
Revenue Q/Q Growth	121.08%	-29.65%	57.07%	166.69%	-65.82%	346.29%	-73.49%	29.90%	-16.95%	225.93%
EBITDA Q/Q Growth	74.52%	196.41%	-330.52%	72.17%	-192.99%	-61.37%	-2.99%	-7.37%	-84.43%	45.78%
EBIT Q/Q Growth	73.12%	186.27%	-343.77%	71.77%	-188.83%	-67.31%	-7.79%	-6.69%	-77.42%	43.37%
NOPAT Q/Q Growth	73.25%	-78.47%	-8.50%	51.27%	-145.75%	1.35%	-35.16%	-16.15%	-14.76%	43.54%
Net Income Q/Q Growth	72.48%	186.91%	-329.86%	80.53%	-302.91%	-91.88%	-2.52%	-19.87%	-66.75%	-7.57%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-60.77%	32.37%	9.35%	-115.18%	46.83%	-249.14%	-0.04%	-18.21%	5.07%	10.42%
Free Cash Flow Firm Q/Q Growth	77.90%	264.62%	-27.67%	-115.98%	-5,586.88%	-58.32%	-3.16%	0.06%	62.11%	110.00%
Invested Capital Q/Q Growth	69.35%	-1,864.08%	26.54%	43.80%	552.99%	32.15%	5.98%	6.26%	-20.11%	-28.71%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.09%	98.91%	96.06%	92.01%	95.03%	90.50%	94.89%	19.69%	37.67%	88.66%
EBITDA Margin	-220.77%	302.52%	-443.99%	-46.34%	-397.24%	-143.63%	-447.42%	-369.81%	-821.24%	-136.62%
Operating Margin	-230.55%	-460.58%	-404.00%	-73.81%	-530.71%	-117.31%	-598.13%	-534.84%	-739.00%	-128.01%
EBIT Margin	-234.62%	287.69%	-446.47%	-47.26%	-399.38%	-149.72%	-493.02%	-404.92%	-865.01%	-150.30%
Profit (Net Income) Margin	-230.20%	284.37%	-416.15%	-30.38%	-358.10%	-153.96%	-485.31%	-447.85%	-899.19%	-296.76%
Tax Burden Percent	99.50%	88.89%	99.23%	97.20%	101.74%	100.00%	99.58%	100.35%	100.00%	175.47%
Interest Burden Percent	98.61%	111.21%	93.94%	66.13%	88.13%	102.83%	98.85%	110.21%	103.95%	112.52%
Effective Tax Rate	0.00%	11.11%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	-453.13%	-205.33%	-824.79%	-501.28%	-414.59%	-69.88%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	-453.71%	-189.19%	-819.84%	-491.31%	-377.52%	51.90%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	377.30%	158.85%	627.99%	319.14%	209.42%	-20.94%
Return on Equity (ROE)	-31.24%	-26.48%	-39.53%	-19.86%	-75.83%	-46.48%	-196.80%	-182.13%	-205.18%	-90.82%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-212.44%	-234.58%	-230.56%	-240.86%	-215.99%	-157.45%
Operating Return on Assets (OROA)	-19.59%	23.55%	-36.03%	-6.80%	-51.17%	-28.59%	-105.95%	-76.76%	-128.18%	-20.25%
Return on Assets (ROA)	-19.23%	23.28%	-33.58%	-4.37%	-45.88%	-29.39%	-104.30%	-84.90%	-133.24%	-39.99%
Return on Common Equity (ROCE)	-31.24%	-26.48%	-39.53%	-19.86%	-75.83%	-46.48%	-196.80%	-182.13%	-205.18%	-90.82%
Return on Equity Simple (ROE_SIMPLE)	-37.56%	0.00%	-53.39%	-24.32%	-30.25%	0.00%	-101.30%	-205.70%	-128.51%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.64	-8.28	-8.98	-4.38	-11	-11	-14	-17	-19	-11
NOPAT Margin	-161.38%	-409.39%	-282.80%	-51.67%	-371.50%	-82.12%	-418.69%	-374.39%	-517.30%	-89.61%
Net Nonoperating Expense Percent (NNEP)	-1.75%	12.88%	-4.20%	2.05%	0.58%	-16.14%	-4.96%	-9.97%	-37.07%	-121.78%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-10.14%	-	-	-	-10.88%
Cost of Revenue to Revenue	4.91%	1.09%	3.94%	7.99%	4.97%	9.50%	5.11%	80.31%	62.33%	11.34%
SG&A Expenses to Revenue	138.27%	236.00%	227.55%	78.06%	200.97%	113.44%	289.96%	283.30%	438.65%	133.90%
R&D to Revenue	187.37%	323.49%	272.51%	87.76%	424.77%	88.40%	358.45%	236.48%	296.21%	69.35%
Operating Expenses to Revenue	325.64%	559.50%	500.06%	165.82%	625.73%	207.82%	693.02%	554.53%	776.67%	216.67%
Earnings before Interest and Taxes (EBIT)	-6.74	5.82	-14	-4.00	-12	-19	-17	-18	-32	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.35	6.12	-14	-3.93	-12	-19	-15	-16	-30	-16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.29	2.11	2.66	2.52	2.42	3.83	4.30	6.31	5.23	11.22
Price to Tangible Book Value (P/TBV)	2.29	2.11	2.66	2.52	2.42	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	20.08	15.59	20.27	10.45	9.87	8.64	7.58	8.66	14.91	18.85
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	4.44	5.75	5.12	5.15	9.90	18.14
Enterprise Value to Revenue (EV/Rev)	11.26	6.72	11.48	5.93	7.49	7.73	7.23	9.04	13.42	18.18
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.14	0.17	0.18	0.19	0.65	0.69	0.88	1.80	0.84	1.50
Long-Term Debt to Equity	0.14	0.17	0.18	0.19	0.65	0.08	0.88	1.80	0.84	1.50
Financial Leverage	-1.00	-1.08	-1.04	-1.05	-0.83	-0.84	-0.77	-0.65	-0.55	-0.40
Leverage Ratio	1.14	1.23	1.20	1.37	1.60	2.10	2.15	2.48	2.41	3.45
Compound Leverage Factor	1.12	1.37	1.13	0.91	1.41	2.16	2.12	2.73	2.50	3.88
Debt to Total Capital	12.01%	14.56%	15.32%	15.65%	39.40%	40.87%	46.83%	64.23%	45.78%	60.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	36.03%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	12.01%	14.56%	15.32%	15.65%	39.40%	4.84%	46.83%	64.23%	45.78%	60.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.99%	85.44%	84.68%	84.35%	60.60%	59.13%	53.17%	35.77%	54.22%	40.00%
Debt to EBITDA	-0.36	-0.47	-0.33	-0.70	-1.87	-0.89	-0.87	-0.94	-0.73	-0.75
Net Debt to EBITDA	2.64	3.33	2.10	4.09	1.69	0.52	0.20	-0.15	0.45	0.20
Long-Term Debt to EBITDA	-0.36	-0.47	-0.33	-0.70	-1.87	-0.11	-0.87	-0.94	-0.73	-0.75
Debt to NOPAT	-0.51	-0.43	-0.34	-0.52	-1.43	-1.23	-1.07	-1.11	-0.97	-0.98
Net Debt to NOPAT	3.74	3.02	2.20	3.05	1.29	0.72	0.24	-0.17	0.60	0.26
Long-Term Debt to NOPAT	-0.51	-0.43	-0.34	-0.52	-1.43	-0.15	-1.07	-1.11	-0.97	-0.98
Altman Z-Score	2.18	-0.84	-0.32	-0.52	-1.21	-2.08	-2.55	-3.13	-1.65	-1.90
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.10	7.72	6.68	5.67	6.31	1.18	2.10	2.00	2.88	2.53
Quick Ratio	9.78	7.58	6.60	5.56	6.23	1.15	2.04	1.91	2.82	2.35
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3.64	6.00	4.34	-0.69	-39	-62	-64	-64	-24	2.44
Operating Cash Flow to CapEx	-23,564.29%	-13,123.53%	-13,948.28%	-37,843.48%	-2,690.70%	-22,441.67%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	-113.92	0.00	-34.98	-19.31	1.08
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	-29.49	0.00	-10.39	-14.36	-7.17
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-29.62	0.00	-10.39	-14.36	-7.17
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.08	0.08	0.08	0.14	0.13	0.19	0.21	0.19	0.15	0.13
Accounts Receivable Turnover	2.61	2.07	1.68	1.96	2.01	2.14	3.44	2.06	2.76	1.69
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	12.03	12.11	11.87	20.77	22.17	35.90	38.51	34.66	39.21	43.25
Accounts Payable Turnover	0.40	0.05	0.05	0.14	0.11	0.13	0.18	0.38	0.43	0.28
Days Sales Outstanding (DSO)	139.62	176.50	216.97	185.93	181.92	170.64	106.21	177.04	132.03	215.53
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	922.50	7,568.82	6,826.25	2,668.47	3,272.75	2,903.54	2,003.72	959.19	851.15	1,325.23
Cash Conversion Cycle (CCC)	-782.88	-7,392.32	-6,609.29	-2,482.54	-3,090.83	-2,732.90	-1,897.51	-782.15	-719.12	-1,109.70
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.76	-15	-11	-6.16	28	37	39	42	33	24
Invested Capital Turnover	-40.76	-1.30	-2.18	-3.83	1.22	2.50	1.97	1.34	0.80	0.78
Increase / (Decrease) in Invested Capital	-0.99	-14	-13	-3.68	29	52	50	48	5.28	-13
Enterprise Value (EV)	121	68	108	98	124	212	200	214	329	429
Market Capitalization	215	158	190	173	164	237	210	205	365	445
Book Value per Share	$2.72	$2.18	$2.07	$2.02	$1.99	$1.71	$1.35	$0.78	$1.33	$0.74
Tangible Book Value per Share	$2.72	$2.18	$2.07	$2.02	$1.99	($0.33)	($0.65)	($0.92)	($0.11)	($0.64)
Total Capital	107	88	84	81	111	105	92	91	129	99
Total Debt	13	13	13	13	44	43	43	58	59	60
Total Long-Term Debt	13	13	13	13	44	5.07	43	58	59	60
Net Debt	-95	-90	-82	-75	-40	-25	-9.72	9.07	-37	-16
Capital Expenditures (CapEx)	0.03	0.03	0.03	0.02	0.17	0.07	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.81	-2.04	-6.62	-2.20	32	-17	-20	-19	-24	-18
Debt-free Net Working Capital (DFNWC)	77	81	89	85	115	51	33	30	65	52
Net Working Capital (NWC)	77	81	89	85	115	13	33	30	65	52
Net Nonoperating Expense (NNE)	1.98	-14	4.24	-1.80	-0.39	9.28	2.28	3.27	14	25
Net Nonoperating Obligations (NNO)	-95	-90	-82	-75	-40	-25	-9.72	9.07	-37	-16
Total Depreciation and Amortization (D&A)	0.40	0.30	0.08	0.08	0.06	0.79	1.56	1.56	1.62	1.65
Debt-free, Cash-free Net Working Capital to Revenue	7.56%	-20.04%	-70.64%	-13.28%	192.43%	-61.25%	-71.22%	-79.43%	-99.70%	-74.26%
Debt-free Net Working Capital to Revenue	715.44%	795.31%	946.05%	514.90%	696.12%	185.42%	119.02%	128.51%	265.27%	220.07%
Net Working Capital to Revenue	715.44%	795.31%	946.05%	514.90%	696.12%	48.13%	119.02%	128.51%	265.27%	220.07%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.19)	$0.16	($0.34)	($0.15)	($0.40)	($0.54)	($0.40)	($0.48)	($0.69)	($0.71)
Adjusted Weighted Average Basic Shares Outstanding	34.49M	34.49M	34.47M	33.90M	34.72M	35.45M	41.78M	41.90M	47.81M	46.25M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	34.50M	34.54M	33.88M	33.93M	36.22M	43.43M	41.85M	52.62M	53.38M	54.12M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	34.50M	34.54M	33.88M	33.93M	36.22M	43.43M	41.85M	52.62M	53.38M	54.12M
Normalized Net Operating Profit after Tax (NOPAT)	-4.64	-8.28	-8.98	-4.38	-11	-11	-14	-17	-19	-11
Normalized NOPAT Margin	-161.38%	-409.39%	-282.80%	-51.67%	-371.50%	-82.12%	-418.69%	-374.39%	-517.30%	-89.61%
Pre Tax Income Margin	-231.35%	319.93%	-419.40%	-31.25%	-351.99%	-153.96%	-487.36%	-446.28%	-899.19%	-169.13%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-35.30	0.00	-9.79	-25.31	-7.98
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-19.36	0.00	-9.05	-15.13	-4.76
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-35.43	0.00	-9.79	-25.31	-7.98
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-19.49	0.00	-9.05	-15.13	-4.76
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-13.71%	-17.64%	-9.04%	-20.29%	-16.56%	-7.49%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Zevra Therapeutics (ZVRA) quarterly statements over the last four years, focusing on trends in revenue, profitability, cash flow, and the balance sheet that may matter to retail investors.

Gross margin expansion in Q4 2024: gross profit of 10.677M on revenue of 12.043M yields a margin of about 88.7%, marking a notable improvement from earlier quarters.
Significant equity financing in Q3 2024: net cash from financing activities was about 64.8M due to equity issuance, boosting liquidity.
Debt financing activity in Q2 2024: issuance of debt contributed roughly 59.0M of net cash from financing activities, enhancing liquidity temporarily.
Solid near-term liquidity in Q3 2024: cash and equivalents were around 54M, providing a liquidity runway into late 2024.
Operating expense flexibility in Q4 2024: total operating expenses declined to about 26.1M from 28.7M in Q3 2024, improving operating leverage.
Q4 2024 revenue uptick: revenue rose to 12.043M from 3.695M in Q3 2024, suggesting a potential top-line uptick, though profitability remains elusive.
Consistent amortization expense: amortization runs around 1.5M per quarter, a relatively small, steady non-cash expense.
High ongoing R&D and SG&A investments: quarterly spend in the high-teens to high-tens of millions, indicating persistent investment activity even as losses continue.
Significant net losses persist in Q4 2024: net income of -35.739M, with basic/diluted loss per share around -0.71 to -0.69 in recent quarters.
Ongoing cash burn from operations: net cash from continuing operating activities is negative in all four quarters (roughly -16M to -19M per quarter), signaling persistent cash burn from core operations.

05/14/26 07:51 AM ETAI Generated. May Contain Errors.

Zevra Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Zevra Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Zevra Therapeutics' net income appears to be on an upward trend, with a most recent value of -$105.51 million in 2024, rising from -$26.77 million in 2022. The previous period was -$46.05 million in 2023. See where experts think Zevra Therapeutics is headed by visiting Zevra Therapeutics' forecast page.

Zevra Therapeutics' total operating income in 2024 was -$87.00 million, based on the following breakdown:

Total Gross Profit: $16.20 million
Total Operating Expenses: $103.20 million

Over the last 2 years, Zevra Therapeutics' total revenue changed from $10.16 million in 2022 to $23.61 million in 2024, a change of 132.4%.

Zevra Therapeutics' total liabilities were at $138.46 million at the end of 2024, a 25.3% increase from 2023, and a 244.3% increase since 2022.

In the past 2 years, Zevra Therapeutics' cash and equivalents has ranged from $33.79 million in 2024 to $65.47 million in 2022, and is currently $33.79 million as of their latest financial filing in 2024.

Over the last 2 years, Zevra Therapeutics' book value per share changed from 2.18 in 2022 to 0.74 in 2024, a change of -65.9%.

Related Companies

Financial statements for NASDAQ:ZVRA last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zevra Therapeutics (ZVRA) Financials

Financials Breakdown Chart

Key Financial Trends

Zevra Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zevra Therapeutics (ZVRA) Financials

Annual Income Statements for Zevra Therapeutics

Quarterly Income Statements for Zevra Therapeutics

Annual Cash Flow Statements for Zevra Therapeutics

Quarterly Cash Flow Statements for Zevra Therapeutics

Annual Balance Sheets for Zevra Therapeutics

Quarterly Balance Sheets for Zevra Therapeutics

Annual Metrics And Ratios for Zevra Therapeutics

Quarterly Metrics And Ratios for Zevra Therapeutics

Financials Breakdown Chart

Key Financial Trends

Zevra Therapeutics Financials - Frequently Asked Questions

When does Zevra Therapeutics' financial year end?

How has Zevra Therapeutics' net income changed over the last 2 years?

What is Zevra Therapeutics' operating income?

How has Zevra Therapeutics' revenue changed over the last 2 years?

How much debt does Zevra Therapeutics have?

How much cash does Zevra Therapeutics have?

How has Zevra Therapeutics' book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools